Network meta-analysis of therapies for previously untreated advanced BRAF-mutated melanoma

Until recently, effective treatment options for patients with advanced stage melanoma were limited. Indeed, according to a 2011 systematic review of treatment options in melanoma, patients with metastatic disease had a median survival of under one year [1]. However, recent developments in understanding molecular mechanisms of oncogenesis, including the role of the mitogen-activated protein kinase (MAPK) signaling pathway, have led to the introduction of a number of novel treatment options. Approximately 40-70% of advanced melanoma cases harbor a BRAF mutation, causing constitutive activation of the MAPK pathway [1 –4].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Systematic or Meta-analysis Studies Source Type: research